Federico Massa (@fedemassa88) profile picture

Neurologist, PhD in Clinical and Experimental Neuroscience and research fellow at DINOGMI, University of Genoa, Italy, and Policlinico San Martino IRCCS.

Genova, Liguria
Joined February 2013
The early and accurate detection of #AlzheimersDisease enables patients and their care partners to plan for the future and make appropriate lifestyle changes that could help maintain their quality of life for longer.³ Watch Dr. Massa’s opinion on this topic here:
7
15
103,948
Federico Massa retweeted
Barba et al. review the co-occurrence of Alzheimer's disease and Lewy body disease pathologies, and consider the diagnostic and prognostic value of neuroimaging and fluid biomarkers. tinyurl.com/mt5cxbuv
36
100
12,501
Thank you for an amazing 5 days filled with science, inspiring talks, insights, and networking! 🤩 We hope to welcome you again at the next edition of AD/PD™ on April 1-5, 2025 in Vienna, Austria. 📅 Stay tuned for more information! #ADPD2025
3
5
1
56
4,812
Watch our latest video from this year’s #ADPD24 in Lisbon. Dr. Federico Massa shares his thoughts on identifying genetic causes underlying #AlzheimersDisease.¹ For Healthcare professionals.
4
17
71,762
Federico Massa retweeted
Honored to share this excellent meta-analysis out on JNNP! All levels (even low levels) of leisure-time physical activity are beneficial for stroke prevention 🏃🏻‍♂️🧠 @RaffaeleOrnello @s_rumeileh @mattfos89 @fededs00 @MicheleRomoli @luciodanna2 @Simona_Sacco_ jnnp.bmj.com/content/early/2…
8
1
14
1,254
If interested in molecular imaging biomarkers for early diagnosis and prognosis of early-stage dementias, see our updated systematic review of recent literature. #MCI #dementia #PET #Alzheimer #nuclearmedicine See EJNMMI:rdcu.be/dyFyf link.springer.com/article/10…
1
4
99
Could not be prouder for contributing to this oustanding project: European expert-shared recommendations for a cost-effettive use of biomarkers in early dementia are now on @TheLancetNeuro Have a glance: authors.elsevier.com/c/1ibhs… @GiovanniFrisoni @SanMartino_Ge @UniGenova
1
46
Happy to share our work published with @SpringerNature on J of Neurology. If interested on the changes of cerebrospinal fluid levels of NPTX2 and association with brain metabolism metrics in MCI-AD, just read and share: rdcu.be/duMvN 🇮🇹🇩🇪🧠 @UniGenova @SanMartino_Ge
3
5
252
Federico Massa retweeted
Honored to share my first #Neurology paper! In this work, we show that CSF synaptic biomarkers (SNAP25, ng, α-syn, β-syn) are similarly increased in patients with AD and mixed LBD-AD compared to controls and pure LBD cases 💉🧠😃 @s_rumeileh @GreenJournal n.neurology.org/content/earl…
2
6
25
6,938
Dear all, happy to share our recently published article on Pisa syndrome!!! Right posterior hypometabolism in Pisa syndrome of Parkinson’s disease: A key to explain body schema perception deficit? prd-journal.com/article/S135… @ParkinsonismD
3
11
523
We are glad to announce the first article of the 'European Consensus for the diagnosis of MCI and mild dementia', in which the #EANM participated! Stay tuned for further articles on this initiative. Many thanks to the EANM Neuroimaging Committee! doi.org/10.1002/alz.12798
4
11
Federico Massa retweeted
Excited to share our last paper published in @JNNP_BMJ, in which we highlight the remarkable increase of CSF beta-synuclein in the preclinical phase of #Alzheimer disease 🧠🇮🇹🇩🇪 @s_rumeileh @fedemassa88 @unimedhal @UniperugiaNews jnnp.bmj.com/content/early/2…
1
2
4
Federico Massa retweeted
Study found that early-onset #dementia with Lewy bodies (DLB) was often misdiagnosed as Alzheimer disease, while #Alzheimerdisease co-pathology was more common in later-onset DLB. ja.ma/3nRBC4T
1
4
14
A history of hypothyroidism is associated with an increased risk of dementia in people aged ≥65 years n.neurology.org/cgi/content/…
4
7
👀Markers of #Alzheimer in #plasma measured in an automated platform showed a great accuracy The details have been presented by Dr. Alcolea in the 3rd #CSFSociety meeting held in Berlin 👇🏼
5
26
Thanks @alzforum for covering our preprint about clinical progression in PET-based A+T+ cognitively normal individuals. @alexa_pichetb @OskarHansson9
People with positive amyloid tau PET scans slid from cognitively intact to impaired within 3.5 years. They were 20 times likelier to develop MCI or #dementia than people without these deposits. @lunduniversity ow.ly/gMpJ50JM7xq
7
29